Mitsubishi UFJ Trust & Banking’s Celldex Therapeutics CLDX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+5,773	New	+$186K	﹤0.01%	1315

Other funds holding CLDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CLDX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 5,773 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #1315 among its holdings.

78 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 5,773 shares of Celldex Therapeutics worth $215K as of Q2 2026.
Celldex Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1315 holding.
78 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.